What is it?
Shark cartilage is most famously used for cancer. Shark cartilage is also used for osteoarthritis, plaque psoriasis, age-related vision loss, wound healing, damage to the retina of the eye due to diabetes, and inflammation of the intestine (enteritis).
Some people apply shark cartilage directly to the skin for arthritis and psoriasis.
Some people apply shark cartilage into the rectum for cancer.
How effective is it?
Natural Medicines Comprehensive Database rates effectiveness based on scientific evidence according to the following scale: Effective, Likely Effective, Possibly Effective, Possibly Ineffective, Likely Ineffective, Ineffective, and Insufficient Evidence to Rate.
The effectiveness ratings for SHARK CARTILAGE are as follows:
Likely ineffective for...
- Cancer. Most research shows that taking shark cartilage by mouth does not benefit people with advanced, previously treated cancers of the breast, colon, lung, prostate, or brain. It also doesn't seem to benefit people with advanced, previously treated non-Hodgkin's lymphoma. Shark cartilage has not been studied in people with less advanced cancer.
Insufficient evidence to rate effectiveness for...
- Cancerous tumor called Kaposi sarcoma. There are reports that applying shark cartilage to the skin might decrease tumors called Kaposi sarcoma. These tumors are more common in people with HIV.
- Osteoarthritis. When applied to the skin, products containing shark cartilage in combination with other ingredients reportedly reduce arthritis symptoms. However, any symptom relief is most likely due the camphor ingredient and not the other ingredients. Additionally, there is no research showing that shark cartilage is absorbed through the skin.
- Psoriasis. Early research in people with plaque psoriasis shows that a specific shark cartilage extract (AE-941) improves the appearance of plaques and decreases itching when taken by mouth or applied to the skin.
- A type of kidney cancer called renal cell carcinoma. Taking a specific shark cartilage extract (AE-941) by mouth might increase survival in patients with renal cell carcinoma.
- Age-related vision loss.
- Wound healing.
- Other conditions.
How does it work?
Are there safety concerns?
It can cause a bad taste in the mouth, nausea, vomiting, stomach upset, constipation, low blood pressure, dizziness, high blood sugar, high calcium levels, weakness, and fatigue. It might also cause liver dysfunction. Some products have an unpleasant odor and taste.
Special precautions & warnings:Pregnancy and breast-feeding: There is not enough reliable information about the safety of taking shark cartilage if you are pregnant or breast-feeding. Stay on the safe side and avoid use.
"Autoimmune diseases" such as multiple sclerosis (MS), lupus (systemic lupus erythematosus, SLE), rheumatoid arthritis (RA), or other conditions: Shark cartilage might cause the immune system to become more active. This could increase the symptoms of autoimmune diseases. If you have one of these conditions, it's best to avoid using shark cartilage.
High calcium levels (hypercalcemia): Shark cartilage might increase calcium levels, so it should not be used by people whose calcium levels are already too high.
Are there interactions with medications?
- Medications that decrease the immune system (Immunosuppressants)
- Shark cartilage might increase the immune system. By increasing the immune system, shark cartilage might decrease the effectiveness of medications that decrease the immune system.
Some medications that decrease the immune system include azathioprine (Imuran), basiliximab (Simulect), cyclosporine (Neoral, Sandimmune), daclizumab (Zenapax), muromonab-CD3 (OKT3, Orthoclone OKT3), mycophenolate (CellCept), tacrolimus (FK506, Prograf), sirolimus (Rapamune), prednisone (Deltasone, Orasone), corticosteroids (glucocorticoids), and others.
Are there interactions with herbs and supplements?
- Shark cartilage might raise calcium levels. There is a concern that using it along with calcium supplements might make calcium levels too high.
Are there interactions with foods?
- Fruit juice
- Acidic fruit juice such as orange, apple, grape, or tomato, can lower the strength of shark cartilage as the minutes pass. If shark cartilage is added to a fruit juice, it should be added right before use.
What dose is used?
To learn more about how this article was written, please see the Natural Medicines Comprehensive Database methodology.
- Merly L, Smith SL. Pro-inflammatory properties of shark cartilage supplement. Immunopharmacol Immunotoxicol. 2015;37:140-7. View abstract.
- Sakai S, Otake E, Toida T, Goda Y. Identification of the origin of chondroitin sulfate in "health foods". Chem Pharm Bull (Tokyo). 2007;55:299-303. View abstract.
- PDQ Integrative, Alternative, and Complementary Therapies Editorial Board. Cartilage (Bovine and Shark) (PDQ®): Health Professional Version. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. 2016 Jul 21. View abstract.
- Goldman E. Shark cartilage extract tried as a novel psoriasis treatment. Skin All News 1998;29:14.
- Food and Drug Administration. FDA takes action against firm marketing unapproved drugs. FDA talk paper (December 10, 1999)
- Lane W and Milner M. A comparison of shark cartilage and bovine cartilage. Townsend Lett 1996;153:40-42.
- Zhuang, L, Wang, B, Shivji, G, and et al. AE-941, a novel inhibitor of angiogenesis has significant anti-inflammatory effect on contact hypersensitivity. J Invest Derm 1997;108:633.
- Turcotte P. Phase I dose escalation study of AE-941, an antiangiogenic agent, in age-related macular degeneration patient. Retina Society Conference (Hawaii, December 2, 1999).
- Saunder DN. Angiogenesis antagonist as treatment for psoriasis: Phase I clinical trial results with AE-941. American Academy of Dermatology Conference, New Orleans, Louisiana, March 19-24, 1999.
- Aeterna Laboratories Inc. Phase III randomized study of AE-941 (Neovastat; Shark Cartilage Extract) in patients with metastatic renal cell carcinoma refractory to immunotherapy. 2001.
- Escudier, B, Patenaude, F, Bukowski, R, and et al. Rationale for a phase III clinical trial with AE-941 (Neovastat (R)) in metastatic renal cell carcinoma patients refractory to immunotherapy. Ann Oncol 2000;11(supplement 4):143-144.
- Dupont E, Alaoui-Jamali M, Wang T, and et al. Angiostatic and antitumoral activity of AE-941 (Neovastat), a molecular fraction derived from shark cartilage. Proceedings of the American Association for Cancer Research 1997;38:227.
- Shimizu-Suganuma, Masum, Mwanatambwe, Milanga, Iida, Kazum, and et al. Effect of shark cartilage on tumor growth and survival time in vivo (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1999;18:A1760.
- Anonymous. Angiostatic and antitumoral activity of AE-941 (neovastat-R), a molecular fraction derived from shark cartilage (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 1997;38:A1530.
- Cataldi, JM and Osborne, DL. Effects of shark cartilage on mammary tumor neovascularization in vivo and cell proliferation in vitro (meeting abstract). FASEB Journal 1995;9:A135.
- Jamali MA, Riviere P, Falardeau A, and et al. Effect of AE-941 (Neovastat), an angiogenesis inhibitor, in the Lewis lung carcinoma metastatic model, efficacy, toxicity prevention and survival. Clin Invest Med 1998;(suppl):S16.
- Saad F, Klotz L, Babaian R, Lacombe L, Champagne P, and Dupont E. Phase I/II trial on AE-941 (Neovastat) in patients with metastatic refractory prostate cancer (abstract presentation). Canadian Urological Association Annual Meeting (June 24-27, 2001).
- Rosenbluth, RJ, Jennis, AA, Cantwell, S, and et al. Oral shark cartilage in the treatment of patients with advanced primary brain tumors. A phase II pilot study (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1999;18:A554.
- Dupont E, Savard RE, Jourdain C, Juneau C, Thibodeau A, Ross N, and et al. Antiangiogenic properties of a novel shark cartilage extract: potential role in the treatment of psoriasis. J Cutan Med Surg 1998;2:146-152.
- Lane IW and Contreras E. High rate of bioactivity (reduction in gross tumor size) observed in advanced cancer patients treated with shark cartilage material. J Naturopath Med 1992;3:86-88.
- Wilson JL. Topical shark cartilage subdues psoriasis. Altern Comp Ther 2000;6:291.
- Riviere M, Latreille J, and Falardeau P. AE-941 (Neovastat), an inhibitor of angiogenesis: phase I/II cancer clinical trial results. Cancer Invest 1999;17(suppl 1):16-17.
- Milner M. A guide to the use of shark cartilage in the treatment of arthritis and other inflammatory joint diseases. Amer Chiropractor 1999;21:40-42.
- Leitner SP, Rothkopf MM, Haverstick DD, and et al. Two phase II studies of oral dry shark cartilage powder (SCP) in patients with either metastatic breast or prostate cancer refractory to standard treatment. Amer Soc Clin Oncol 1998;17:A240.
- Evans WK, Latreille J, Batist G, and et al. AE-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non-small-cell lung cancer (NSCLC). Proffered Papers 1999;S250.
- Riviere M, Falardeau P, Latreille J, and et al. Phase I/II lung cancer clinical trial results with AE-941 (Neovastat ®) an inhibitor of angiogenesis. Clin Invest Med (supplement) 1998;S14.
- Riviere M, Alaoui-Jamali M, Falardeau P, and et al. Neovastat: an inhibitor of angiogenesis with anti-cancer activity. Proc Amer Assoc Cancer Res 1998;39:46.
- No authors. Neovastat clinical trial abstracts. 2001;
- Aeterna Laboratories Inc. Phase II study of AE-941 (Neovastat; Shark Cartilage) in patients with early relapse or refractory multiple myeloma. 2001. Information Contact Number 1-888-349-3232.
- Felzenszwalb, I., Pelielo de Mattos, J. C., Bernardo-Filho, M., and Caldeira-de-Araujo, A. Shark cartilage-containing preparation: protection against reactive oxygen species. Food Chem Toxicol 1998;36:1079-1084. View abstract.
- Coppes, M. J., Anderson, R. A., Egeler, R. M., and Wolff, J. E. Alternative therapies for the treatment of childhood cancer. N Engl.J Med 9-17-1998;339:846-847. View abstract.
- Davis, P. F., He, Y., Furneaux, R. H., Johnston, P. S., Ruger, B. M., and Slim, G. C. Inhibition of angiogenesis by oral ingestion of powdered shark cartilage in a rat model. Microvasc.Res 1997;54:178-182. View abstract.
- McGuire, T. R., Kazakoff, P. W., Hoie, E. B., and Fienhold, M. A. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-alpha in human umbilical vein endothelium. Pharmacotherapy 1996;16:237-244. View abstract.
- Kuettner, K. E. and Pauli, B. U. Inhibition of neovascularization by a cartilage factor. Ciba Found.Symp. 1983;100:163-173. View abstract.
- Lee, A. and Langer, R. Shark cartilage contains inhibitors of tumor angiogenesis. Science 9-16-1983;221:1185-1187. View abstract.
- Korman, D. B. [Antiangiogenic and antitumor properties of cartilage]. Vopr.Onkol. 2012;58:717-726. View abstract.
- Patra, D. and Sandell, L. J. Antiangiogenic and anticancer molecules in cartilage. Expert.Rev Mol.Med 2012;14:e10. View abstract.
- de Mejia, E. G. and Dia, V. P. The role of nutraceutical proteins and peptides in apoptosis, angiogenesis, and metastasis of cancer cells. Cancer Metastasis Rev 2010;29:511-528. View abstract.
- Bargahi, A., Hassan, Z. M., Rabbani, A., Langroudi, L., Noori, S. H., and Safari, E. Effect of shark cartilage derived protein on the NK cells activity. Immunopharmacol.Immunotoxicol. 2011;33:403-409. View abstract.
- Lee, S. Y. and Chung, S. M. Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2 alpha suppression. Vascul.Pharmacol 2007;47(5-6):313-318. View abstract.
- Pearson, W., Orth, M. W., Karrow, N. A., Maclusky, N. J., and Lindinger, M. I. Anti-inflammatory and chondroprotective effects of nutraceuticals from Sasha's Blend in a cartilage explant model of inflammation. Mol Nutr Food Res 2007;51:1020-1030. View abstract.
- Kim, S., de, A., V, Bouajila, J., Dias, A. G., Cyrino, F. Z., Bouskela, E., Costa, P. R., and Nepveu, F. Alpha-phenyl-N-tert-butyl nitrone (PBN) derivatives: synthesis and protective action against microvascular damages induced by ischemia/reperfusion. Bioorg.Med Chem 5-15-2007;15:3572-3578. View abstract.
- Merly, L., Simjee, S., and Smith, S. L. Induction of inflammatory cytokines by cartilage extracts. Int Immunopharmacol. 2007;7:383-391. View abstract.
- Moses, M. A., Sudhalter, J., and Langer, R. Identification of an inhibitor of neovascularization from cartilage. Science 6-15-1990;248:1408-1410. View abstract.
- Ratel, D., Glazier, G., Provencal, M., Boivin, D., Beaulieu, E., Gingras, D., and Beliveau, R. Direct-acting fibrinolytic enzymes in shark cartilage extract: potential therapeutic role in vascular disorders. Thromb.Res. 2005;115(1-2):143-152. View abstract.
- Gingras, D., Labelle, D., Nyalendo, C., Boivin, D., Demeule, M., Barthomeuf, C., and Beliveau, R. The antiangiogenic agent Neovastat (AE-941) stimulates tissue plasminogen activator activity. Invest New Drugs 2004;22:17-26. View abstract.
- Latreille, J., Batist, G., Laberge, F., Champagne, P., Croteau, D., Falardeau, P., Levinton, C., Hariton, C., Evans, W. K., and Dupont, E. Phase I/II trial of the safety and efficacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003;4:231-236. View abstract.
- Bukowski, R. M. AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma. Expert.Opin.Investig.Drugs 2003;12:1403-1411. View abstract.
- Jagannath, S., Champagne, P., Hariton, C., and Dupont, E. Neovastat in multiple myeloma. Eur.J.Haematol. 2003;70:267-268. View abstract.
- FDA grants orphan-drug status to Aeterna's Neovastat for kidney cancer. Expert.Rev Anticancer Ther 2002;2:618. View abstract.
- Dupont, E., Falardeau, P., Mousa, S. A., Dimitriadou, V., Pepin, M. C., Wang, T., and Alaoui-Jamali, M. A. Antiangiogenic and antimetastatic properties of Neovastat (AE-941), an orally active extract derived from cartilage tissue. Clin Exp Metastasis 2002;19:145-153. View abstract.
- Beliveau, R., Gingras, D., Kruger, E. A., Lamy, S., Sirois, P., Simard, B., Sirois, M. G., Tranqui, L., Baffert, F., Beaulieu, E., Dimitriadou, V., Pepin, M. C., Courjal, F., Ricard, I., Poyet, P., Falardeau, P., Figg, W. D., and Dupont, E. The Antiangiogenic Agent Neovastat (AE-941) Inhibits Vascular Endothelial Growth Factor-mediated Biological Effects. Clin Cancer Res 2002;8:1242-1250. View abstract.
- Weber, M. H., Lee, J., and Orr, F. W. The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol 2002;20:299-303. View abstract.
- Barber, R., Delahunt, B., Grebe, S. K., Davis, P. F., Thornton, A., and Slim, G. C. Oral shark cartilage does not abolish carcinogenesis but delays tumor progression in a murine model. Anticancer Res 2001;21(2A):1065-1069. View abstract.
- Gonzalez, R. P., Soares, F. S., Farias, R. F., Pessoa, C., Leyva, A., Barros Viana, G. S., and Moraes, M. O. Demonstration of inhibitory effect of oral shark cartilage on basic fibroblast growth factor-induced angiogenesis in the rabbit cornea. Biol.Pharm.Bull. 2001;24:151-154. View abstract.
- Brem, H. and Folkman, J. Inhibition of tumor angiogenesis mediated by cartilage. J Exp.Med 2-1-1975;141:427-439. View abstract.
- Koch, A. E. The role of angiogenesis in rheumatoid arthritis: recent developments. Ann Rheum.Dis. 2000;59 Suppl 1:i65-i71. View abstract.
- Talks, K. L. and Harris, A. L. Current status of antiangiogenic factors. Br J Haematol. 2000;109:477-489. View abstract.
- Morris, G. M., Coderre, J. A., Micca, P. L., Lombardo, D. T., and Hopewell, J. W. Boron neutron capture therapy of the rat 9L gliosarcoma: evaluation of the effects of shark cartilage. Br J Radiol. 2000;73:429-434. View abstract.
- Renckens, C. N. and van Dam, F. S. [The national cancer fund (Koningin Wilhelmina Fonds) and the Houtsmuller-therapy for cancer]. Ned.Tijdschr.Geneeskd. 7-3-1999;143:1431-1433. View abstract.
- Moses, M. A., Wiederschain, D., Wu, I., Fernandez, C. A., Ghazizadeh, V., Lane, W. S., Flynn, E., Sytkowski, A., Tao, T., and Langer, R. Troponin I is present in human cartilage and inhibits angiogenesis. Proc Natl.Acad.Sci.U.S.A 3-16-1999;96:2645-2650. View abstract.
- Moller HJ, Moller-Pedersen T, Damsgaard TE, Poulsen JH. Demonstration of immunogenic keratin sulphate in commercial chondroitin 6-sulfate from shark cartilage. Implications for ELISA assays. Clin Chim Acta 1995;236:195-204. View abstract.
- Lu C, Lee JJ, Komaki R, et al. Chemoradiotherapy with or without AE-941 in stage III non-small cell lung cancer: a randomized phase III trial. J Natl Cancer Inst 2010;102:1-7. View abstract.
- Loprinzi CL, Levitt R, Barton DL, et al. Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial. Cancer 2005;104:176-82. View abstract.
- Batist G, Patenaude F, Champagne P, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002;13:1259-63.. View abstract.
- Sauder DN, Dekoven J, Champagne P, et al. Neovastat (AE-941), an inhibitor of angiogenesis: Randomized phase I/II clinical trial results in patients with plaque psoriasis. J Am Acad Dermatol 2002;47:535-41. View abstract.
- Gingras D, Renaud A, Mousseau N, et al. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001;21:145-55.. View abstract.
- Falardeau P, Champagne P, Poyet P, et al. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001;28:620-5.. View abstract.
- Boivin D, Gendron S, Beaulieu E, et al. The antiangiogenic agent Neovastat (AE-941) induces endothelial cell apoptosis. Mol Cancer Ther 2002;1:795-802.. View abstract.
- Cohen M, Wolfe R, Mai T, Lewis D. A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. J Rheumatol 2003;30:523-8.. View abstract.
- May B, Kuntz HD, Kieser M, Kohler S. Efficacy of a fixed peppermint oil/caraway oil combination in non-ulcer dyspepsia. Arzneimittelforschung 1996;46:1149-53. View abstract.
- Anon. AEterna announces the commencement of patient enrollment for the NIH - sponsored phase III clinical trial of AE-941/Neovastat in the treatment of lung cancer. Aeterna 2000 News Release 2000 May 17.
- Sheu JR, Fu CC, Tsai ML, Chung WJ. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities. Anticancer Res 1998;18:4435-41. View abstract.
- Fontenele JB, Viana GS, Xavier-Filho J, de-Alencar JW. Anti-inflammatory and analgesic activity of a water-soluble fraction from shark cartilage. Braz J Med Biol Res 1996;29:643-6. View abstract.
- Fontenele JB, Araujo GB, de Alencar JW, Viana GS. The analgesic and anti-inflammatory effects of shark cartilage are due to a peptide molecule and are nitric oxide (NO) system dependent. Biol Pharm Bull 1997;20:1151-4. View abstract.
- Gomes EM, Souto PR, Felzenszwalb I. Shark-cartilage containing preparation protects cells against hydrogen peroxide induced damage and mutagenesis. Mutat Res 1996;367:204-8. View abstract.
- Mathews J. Media feeds frenzy over shark cartilage as cancer treatment. J Natl Cancer Inst 1993;85:1190-1. View abstract.
- Bhargava P, Trocky N, Marshall J, et al. A phase I safety, tolerance and pharmacokinetic study of rising dose, rising duration continuous infusion of MSI-1256F (Squalamine Lactate) in patients with advanced cancer. Proc Am Soc Clinical Oncol 1999;18:A698.
- Kalidas M, Hammond LA, Patnaik P, et al. A phase I and pharmacokinetic (PK) study of the angiogenesis inhibitor, squalamine lactate (MSI-1256F). Proc Am Soc Clinical Oncol 2000;19:A698.
- Patnaik A, Rowinsky E, Hammond L, et al. A phase I and pharmacokinetic (PK) study of the unique angiogenesis inhibitor, squalamine lactate (MSI-1256F). Proc Am Soc Clinical Oncol 1999;18:A622.
- Evans WK, Latreille J, Batist G, et al. AE-941, an inhibitor of angiogenesis: rationale for development in combination with induction chemotherapy/radiotherapy in patients with non small cell lung cancer (NSCLC). Proc Am Soc Clinical Oncol 1999;18:A1938.
- Rosenbluth RJ, Jennis AA, Cantwell S, DeVries J. Oral shark cartilage in the treatment of patients with advanced primary brain tumors. A phase II pilot study. Proc Am Soc Clinical Oncol 1999;18:A554.
- Leitner SP, Rothkopf MM, Haverstick L, et al. Two phase II studies of oral dry shark cartilage powder (SCP) in patients (pts) with either metastatic breast or prostate cancer refractory to standard treatment. Proc Am Soc Clinical Oncol 1998;17:A240.
- Natl Cancer Institute CancerNet. Cartilage website: www.cancer.gov (Accessed 18 August 2000).
- Berbari P, Thibodeau A, Germain L, et al Antiangiogenic effects of the oral administration of liquid cartilage extract in humans. J Surg Res 1999;87:108-13. View abstract.
- Hillman JD, Peng AT, Gilliam AC, Remick SC. Treatment of Kaposi Sarcoma with oral administration of shark cartilage in a Human Herpes virus 8-seropositive, Human Immunodeficiency Virus-Seronegative homosexual man. Arch Dermatol 2001;137:1149-52. View abstract.
- Neovastat clinical trial abstracts. Presented at the American Association for Cancer Research 92nd annual meeting. March 27, 2001.
- Wilson JL. Topical shark cartilage subdues psoriasis: research review and preliminary clinical results. Altern Complement Ther 2000;6:291.
- Miller DR, Anderson GT, Stark JJ, et al. Phase I/II trial of the safety and efficacy of shark cartilage in the treatment of advanced cancer. J Clin Oncol 1998;16:3649-55. View abstract.
- Lane IW, Comac L. Sharks don't get cancer. Garden City, NY: Avery Publishing Group; 1992.
- Hunt TJ, Connelly JF. Shark cartilage for cancer treatment. Am J Health Syst Pharm 1995;52:1756-60. View abstract.
- Ashar B, Vargo E. Shark cartilage-induced hepatitis [letter]. Ann Intern Med 1996;125:780-1. View abstract.